迈得医疗工业设备股份有限公司董事会 2024 年 4 月 25 日 迈得医疗工业设备股份有限公司董事会 对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等要求， 迈得医疗工业设备股份有限公司（以下简称"公司"）董事会，就公司 2023 年度 在任独立董事王亚卡、何涛、张颖辉的独立性情况进行评估并出具如下专项意见： 经核查独立董事王亚卡、何涛、张颖辉的任职情况及其签署的相关自查文件， 上述人员未在公司担任除独立董事及董事会各相关专门委员会以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系。因此，公司董事会认为，公司独 立董事符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等规定中对独立董事独立性的相关要求，不存 在影响独立董事独立性的情况。 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2024-018 一、董事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第四届董事会第十九次 会议（以下简称"本次会议"）于 2024 年 4 月 25 日以现场加通讯的方式在公司会 议室召开。本次会议的通知已于 2024 年 4 月 15 日以电子邮件方式送达全体董事。 本次会议由董事长林军华先生召集并主持，应出席会议董事 7 人，实际出席会议 董事 7 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、行政 法规以及《迈得医疗工业设备股份有限公司章程》的相关规定。 二、董事会会议审议情况 经与会董事审议表决，通过了如下议案： (一)审议通过了《关于公司 2023 年度总经理工作报告的议案》 经审议，董事会同意《公司 2023 年度总经理工作报告》。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 迈得医疗工业设备股份有限公司 第四届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 (二)审议通过了《关于公司 ...

公司代码：688310 公司简称：迈得医疗 迈得医疗工业设备股份有限公司 2023 年度内部控制评价报告 迈得医疗工业设备股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的 ...

目 录 | 二、财务报表……………………………………………………… 第 8—15 | | | 页 | | --- | --- | --- | --- | | （一）合并资产负债表…………………………………………… | 第 | 8 页 | | | （二）母公司资产负债表………………………………………… | 第 | 9 页 | | | （三）合并利润表…………………………………………………第 | 10 | 页 | | | （四）母公司利润表………………………………………………第 | 11 | 页 | | | （五）合并现金流量表……………………………………………第 | 12 | 页 | | | （六）母公司现金流量表…………………………………………第 | 13 | 页 | | --- | --- | --- | | （七）合并所有者权益变动表……………………………………第 | 14 | 页 | （八）母公司所有者权益变动表…………………………………第 15 页 | | | 审 计 报 告 天健审〔2024〕3903 号 迈得医疗工业设备股份有限公司全体股东： 一、审计意见 我们审计了迈得医疗工业设备股份有限公司（ ...

Financial Performance - In 2023, the company's operating revenue reached ¥480,220,256, representing a 25.22% increase compared to ¥383,489,867 in 2022[22]. - The net profit attributable to shareholders was ¥99,828,174, up 48.94% from ¥67,024,645 in the previous year[22]. - The net profit after deducting non-recurring gains and losses increased by 51.35% to ¥87,181,211 from ¥57,601,750 in 2022[22]. - The cash flow from operating activities was ¥110,908,655, a 13.94% increase from ¥97,339,070 in 2022[22]. - The company's total assets grew by 10.75% to ¥1,149,858,762 from ¥1,038,264,311 at the end of 2022[22]. - The basic earnings per share rose to ¥0.85, reflecting a 49.12% increase from ¥0.57 in 2022[23]. - The gross profit margin improved from 50.46% in 2022 to 52.27% in 2023, reflecting the company's ability to maintain pricing power despite rising costs[134]. - The company's main business revenue from specialized equipment manufacturing was CNY 476.26 million, a 25.36% increase year-on-year[145]. Research and Development - The company submitted 56 new patent applications during the reporting period, including 6 invention patents[37]. - A total of 32 new patents were granted, with 3 being invention patents, enhancing the company's intellectual property portfolio[37]. - The company has established a comprehensive R&D system integrating eight major modules, including materials, mechanics, and software, reflecting its commitment to high-tech industry standards[95]. - The company has developed multiple core technologies in the field of medical consumables intelligent equipment, establishing itself as a leading domestic manufacturer[92]. - The company has achieved significant advancements in dialysis membrane packaging technology, reducing defects such as blockage (0.1%) and membrane scattering (0.1%) through automated production processes[93]. - The company has received recognition as a national-level specialized and innovative "little giant" enterprise, highlighting its leadership in the medical consumables sector[95]. - The company is focusing on market expansion opportunities in the domestic and international insulin pen markets[96]. Market Position and Strategy - The company has established subsidiaries in Shanghai, Tianjin, and Germany, expanding its market presence[37]. - The company has maintained the highest market share in the medical device industry in China for the years 2021, 2022, and 2023, indicating strong competitive positioning[63]. - The company is actively involved in drafting industry standards, enhancing its influence in the medical device sector, and contributing to the establishment of quality management norms[63]. - The company is committed to expanding its market presence in Europe and developing countries, aiming to increase market penetration and share[182]. - The company plans to expand its market presence and is focusing on new product development, particularly in the medical equipment sector[197]. Corporate Governance - The company has established a comprehensive corporate governance system, including rules for shareholder meetings, board meetings, and supervisory meetings[188]. - The board of directors includes specialized committees to enhance decision-making processes and ensure objective governance[189]. - The company emphasizes transparency in information disclosure, adhering to legal requirements to protect minority investors' interests[190]. - The company has not faced any significant issues regarding independence from its controlling shareholders or related party transactions[190]. - The company held 3 shareholder meetings in 2023, including 1 annual and 2 extraordinary meetings, with a total of 12 proposals approved[188]. Risks and Challenges - The company has detailed potential risks and countermeasures in the report, emphasizing the importance of investor caution[4]. - The company faces risks related to rapid technological updates and the need for continuous innovation to maintain competitive advantages in the medical equipment sector[129]. - The company has a risk of potential contract non-fulfillment, as seen in a past contract with ARSMED, which could adversely affect future financial performance[135]. Innovation and Technology - The company has made significant advancements in technology, achieving recognition for being the first in the domestic market for several products[41]. - The company has developed a high-precision visual real-time inspection platform, which utilizes the self-developed YOLO V4 target detection algorithm to enhance product quality and reduce defect rates[94]. - The company has implemented a GMP data management platform that ensures data integrity and compliance with national regulations, enhancing production process efficiency[94]. - The company is focusing on automation in production processes, gradually replacing manual labor to enhance efficiency and product quality[90]. Talent Development - The company emphasizes talent development and optimization of training strategies to enhance employee loyalty and skills, ensuring sustainable growth[39]. - The company has a total of 113 R&D personnel, accounting for 15.94% of the total workforce, with an average salary of 15.97 million RMB[109]. - The company has a strong focus on talent development, regularly inviting industry experts for lectures and sending employees for further training[111]. Financial Management - The company's accounts receivable at the end of the reporting period amounted to CNY 135.83 million, accounting for 18.86% of current assets and 11.81% of total assets[137]. - Inventory at the end of the reporting period was valued at CNY 143.71 million, representing 19.95% of current assets and 12.50% of total assets[138]. - The company reported a foreign exchange gain of CNY 0.53 million in 2023, down from CNY 0.68 million in 2022[141]. - The company reported a significant increase in minority interests, rising by 345.29% due to profits from subsidiaries and capital increases[166]. Product Development - The company launched new products such as glass pre-filled syringe cleaning and siliconization packaging machines, contributing to revenue growth[25]. - The company has developed a range of automated assembly machines for various medical devices, including blood collection needles, insulin syringes, and infusion devices, showcasing a comprehensive product line[62]. - The company has introduced new products such as automatic assembly machines for POCT diagnostic reagent storage and ENFit nutrition delivery systems, expanding its product offerings[127].

| 序号 | | 召开日期 | | 会议届次 | 审议议案 | | --- | --- | --- | --- | --- | --- | | 1 | 2023 | 年 | 月 1 | 第四届董事会审计委 | 1、审议《关于首次公开发行股票募投项目结项 并将节余募集资金永久补充流动资金的议案》 | | | 15 日 | | | 员会第六次会议 | 2. 审议《关于确认 2022 年度日常关联交易及预 | | | | | | | 计 2023 年度日常关联交易的议案》 | | 2 | 2023 | 年 | 月 2 | 第四届董事会审计委 | 年年度财务报表（未经 1、审议《关于公司 2022 | | | 15 日 | | | 员会第七次会议 | 审计）的议案》 | | | | | | | 年度财务报告的议案》 1、审议《关于公司 2022 案》 年度内部控制评价报告 3、审议《关于公司 2022 | | | | | | | 2、审议《关于公司 2022 年度财务决算报告的议 | | | | | | | 的议案》 | | | 2023 | 年 | 4 月 | 第四届董事会审计委 | | | 3 | 日 25 | ...

广发证券股份有限公司 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为迈得 医疗工业设备股份有限公司（以下简称"迈得医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 科创板股票上市规则》等法律法规的规定，对迈得医疗在 2023 年度募集资金存 放与使用情况进行了核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会《关于同意迈得医疗工业设备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2019 号），中国证券监督管理委 员会同意公司首次公开发行股票的注册申请。公司于 2019 年 11 月首次公开发行 人民币普通股（A 股）股票 2,090 万股，每股面值人民币 1.00 元，每股发行价格 24.79 元，募集资金总额为人民币 51,811.10 万元，扣除发行费用人民币 6,075.96 万元（不含税）后，募集资金净额为 ...

按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是迈得 医疗公司董事会的责任。 二、注册会计师的责任 目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2024〕3904 号 迈得医疗工业设备股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了迈得医疗工业设备股份有限公司（以下简称迈得医疗公司）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 第 1 页 共 2 页 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 天健会计师事务所（特殊普通合伙） 中国注册会计师： 中国·杭州 中国注册会计师： 二〇二四年四月二十五日 第 2 页 共 2 页 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 74,220,852.42, representing a year-on-year increase of 2.08%[5] - The net profit attributable to shareholders decreased by 21.61% to CNY 10,513,161.20[5] - Net profit for Q1 2024 was CNY 9,614,159.23, a decrease of 38.5% from CNY 15,623,627.82 in Q1 2023[23] - The company reported a total profit of CNY 10,488,149.85 for Q1 2024, down from CNY 18,750,630.03 in Q1 2023, a decline of 44.5%[23] - Other comprehensive income after tax for Q1 2024 was CNY 174,622.57, compared to a loss of CNY 63,413.86 in Q1 2023[23] Cash Flow - The net cash flow from operating activities fell significantly by 75.73% to CNY 10,344,617.70[6] - Cash received from sales of goods and services was CNY 103,629,381.64 in Q1 2024, a decrease of 17.7% from CNY 125,874,771.07 in Q1 2023[26] - Total cash inflow from operating activities amounted to $134,126,952.06, while cash outflow was $123,782,334.36, resulting in a net increase of $10,344,617.70[27] - The net cash flow from investment activities was -$23,828,213.47, compared to -$54,165,252.47 in the previous year, indicating an improvement[27] - The ending balance of cash and cash equivalents was $254,292,535.79, up from $209,923,467.15 in the previous year[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,110,516,301.81, a decrease of 3.42% from the end of the previous year[6] - The total current assets were reported at RMB 681,773,053.34, down from RMB 720,324,715.93, indicating a decrease of about 5.3%[17] - The total liabilities decreased to CNY 160,002,589.04 in Q1 2024 from CNY 209,601,710.61 in Q1 2023, a reduction of 23.7%[19] - The total equity increased to CNY 950,513,712.77 in Q1 2024 from CNY 940,257,051.02 in Q1 2023, showing a growth of 1.3%[19] Research and Development - Research and development expenses totaled CNY 9,880,803.80, an increase of 31.44% compared to the previous year[6] - R&D expenses accounted for 13.31% of operating revenue, up by 2.97 percentage points[6] - Research and development expenses increased to CNY 9,880,803.80 in Q1 2024, compared to CNY 7,517,084.03 in Q1 2023, reflecting a growth of 31.5%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,480[12] - The largest shareholder, Lin Junhua, holds 47.42% of the shares, totaling 55,980,400 shares[12] - The company did not report any significant changes in shareholder structure or related party transactions during the quarter[14] Other Financial Metrics - The weighted average return on net assets was 1.17%, down by 0.45 percentage points[6] - Basic earnings per share for Q1 2024 were CNY 0.09, down from CNY 0.11 in Q1 2023[24] - The company reported a significant drop in receivables financing, which decreased to RMB 32,962,046.45 from RMB 63,482,213.11, a decline of approximately 48%[17] - The company’s goodwill remained stable at RMB 10,423,445.72, unchanged from the previous reporting period[17]

迈得医疗工业设备股份有限公司 关于续聘会计师事务所的公告 证券代码：688310 证券简称：迈得医疗 公告编号：2024-022 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | --- | --- | --- | --- | | 成立日期 | 2011年7月18日 | 组织形式 | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路128号 | | | | 首席合伙人 | 王国海 | 上年末合伙人数量 | 238 人 | | 上年末执业人员数 | 注册会计师 | | 2,272 人 | | 量 | 签署过证券服务业务审计报告 的注册会计师 | | 836人 | | 2023年业务收入 | 业务收入总额 | | 34.83 亿元 | | | 审计业务收入 | | 30.99 亿元 | | | 证券业 ...